SAH & Aneurysm Management
SAH & Aneurysm Management
What You'll Learn
- ISAT trial: coiling superior to clipping for anterior circulation ruptured aneurysms amenable to both; lower death/dependency at 1 year but higher retreatment rates
- Timing: prompt aneurysm identification and treatment, preferably within 24 hours (ideally <12 hours), to prevent rebleeding; rebleeding risk is highest in the first 24 hours (~4–6%)
- Vasospasm peaks days 4–14; nimodipine 60 mg PO q4h × 21 days is the only proven agent; endovascular rescue (intra-arterial vasodilators, balloon angioplasty) for refractory cases
- Unruptured aneurysms: ISUIA data guides management — treat ≥7 mm anterior, ≥5 mm posterior, or symptomatic/growing; PHASES score predicts 5-year rupture risk
- Spetzler-Martin grade guides AVM surgical risk (size + eloquence + deep venous drainage); ARUBA trial favors medical management for unruptured AVMs
- Flow diverters (Pipeline) are indicated for large/giant, wide-neck, or fusiform aneurysms not amenable to standard clipping or coiling
HighYield Pearls
- ISAT bottom line: for ruptured anterior-circulation aneurysms amenable to both, coiling → lower death/dependency at 1 yr (ARR ~7%, NNT ~14); long-term re-rupture marginally higher with coiling but absolute rates <1%; BRAT corroborated.
- Aneurysm choice by anatomy: MCA bifurcation & wide-neck/large mass-effect anterior communicating → clipping favored; posterior circulation & narrow-neck → coiling; wide-neck saccular → balloon- or stent-assisted coiling.
- Flow diverters (Pipeline): giant/fusiform cavernous or ophthalmic ICA aneurysms — obstruct sac inflow + endothelialize across neck; require DAPT × 6 mo + ASA lifelong.
- DAPT obligate: stent-assisted coiling AND flow diverters require dual antiplatelet — problematic in acutely ruptured aneurysm (hemorrhagic risk with EVD/clipping).
- Unruptured — treat if: ≥7 mm anterior or ≥5 mm posterior, irregular morphology, daughter sacs, growth on serial imaging, smoker, family hx (≥2 first-degree relatives), prior SAH, posterior location, or ADPKD.
- PHASES score (Population, HTN, Age, Size, Earlier SAH, Site) predicts 5-yr rupture risk — anchors observe-vs-treat for incidental aneurysms; ISUIA limited generalizability; UCAS Japan adds Asian-population data.
- Screen with MRA: ADPKD (5–10% harbor aneurysms) at 18–30 yr if family hx, then q5 yr; family hx with ≥2 first-degree relatives at age 30; HHT (brain MRI for AVM); FMD; Marfan/Loeys-Dietz.
- Complications to know: intraprocedural rupture (~5% coiling, often fatal); thromboembolism 15–20% periprocedural (DAPT + IV heparin); coil compaction → retreatment 10–20%; clip slip; craniotomy adds seizure, CSF leak, wound infection.
- Post-treatment surveillance: coil → DSA at 6–12 mo then MRA; clip → MRA TOF (susceptibility artifact limits) yearly × few years then less frequent.
- EVD/lumbar drainage post-aSAH: used for acute symptomatic hydrocephalus and ICP management; EVD is common in poor-grade SAH or IVH/hydrocephalus but NOT routine for all patients during the days 4–14 vasospasm window — manage in a multidisciplinary cerebrovascular team.
🔍 Quick ReferenceTreatment choice · Surveillance · Complications
Treatment choice (clip vs coil vs FD)
- Ruptured anterior-circulation, good grade, both feasible → coiling (ISAT)
- MCA bifurcation aneurysm → clipping (BRAT crossover)
- Posterior circulation (basilar tip, PICA) → coiling
- Wide-neck saccular, dome-to-neck <2 → balloon- or stent-assisted coiling (DAPT)
- Giant/fusiform cavernous or ophthalmic ICA → flow diverter (Pipeline) + DAPT × 6 mo
- Large mass-effect, anterior communicating, pediatric → clipping
- Unruptured, PHASES ≥7 mm anterior or ≥5 mm posterior, irregular/daughter sac, smoker → treat
- Low PHASES, small, regular, no risk factors → observe with q1–2 yr MRA
Surveillance / screening
- ADPKD with family hx of aneurysm → MRA at 18–30 yr, repeat q5 yr
- ≥2 first-degree relatives with aneurysm/SAH → MRA at age 30
- HHT (Osler-Weber-Rendu) → brain MRI for AVM + bubble TTE for pulmonary AVM
- Post-coiling follow-up → DSA at 6–12 mo, then MRA
- Post-clipping follow-up → MRA TOF yearly × few yr (susceptibility artifact), then less frequent
- Incidental unruptured aneurysm on observation → q1–2 yr MRA + smoking/HTN modification
Complications
- Intraprocedural rupture during coiling (~5%) → reverse heparin (protamine), continue coiling/balloon tamponade, emergent EVD
- Periprocedural thromboembolism (15–20%) → IV heparin + DAPT; abciximab if intra-stent thrombus
- Coil compaction / recanalization → retreatment in 10–20% (re-coil or stent-assisted)
- Clip slip / residual neck → re-exploration vs adjunctive coiling
- Post-craniotomy seizure, CSF leak, wound infection, hydrocephalus → treat new-onset seizures for 7 days (avoid phenytoin; routine post-aSAH prophylaxis is NOT recommended — consider for high-risk: ruptured MCA aneurysm, IPH, high-grade SAH, hydrocephalus, cortical infarction), CSF diversion, antibiotics
- Flow-diverter delayed parenchymal hemorrhage → continue DAPT, manage HTN, neurosurgical consult
Clipping vs. Coiling: Landmark Trials
ISAT Trial (International Subarachnoid Aneurysm Trial, 2002)
- Design: Largest RCT comparing surgical clipping vs. endovascular coiling — 2,143 patients with ruptured aneurysms amenable to either treatment
- Population: Predominantly anterior circulation (~97%); good clinical grade (WFNS I–II in ~88%)
- Primary endpoint: Death or dependency (modified Rankin Scale 3–6) at 1 year
| Outcome | Coiling | Clipping | Significance |
|---|---|---|---|
| Death or dependency at 1 year | 23.7% | 30.6% | RRR 23.5%; ARR ~7%; NNT ~14; p = 0.0019 |
| Late target-aneurysm rebleeding | Rare in both arms; slightly higher with coiling (~13 vs. ~4 rebleeds over long-term follow-up in Molyneux 2015) — absolute rates <1% in both groups | ||
| Retreatment rate | ~17% | ~4% | Significantly higher with coiling |
| Seizures at 1 year | Lower | Higher | Craniotomy increases seizure risk |
| Survival benefit | Maintained at 5-year, 10-year, and long-term (~18-year) follow-up (Molyneux 2009, 2015, and more recent) | ||
- Bottom line: Coiling preferred when both options are technically feasible; survival benefit is durable but retreatment rates are higher with coiling
- Limitation: Mostly anterior circulation, good-grade patients; does not apply to all aneurysm anatomies
BRAT Trial (Barrow Ruptured Aneurysm Trial, 2012)
- Design: Randomized all SAH patients regardless of aneurysm anatomy; crossover from coil to clip was allowed if coiling was not feasible
- 1-year results: No significant difference in poor outcome (mRS 3–6) between groups overall
- 6-year results: Similar long-term outcomes; higher retreatment rate with coiling
- Key findings by location:
- Posterior circulation aneurysms: Better outcomes with coiling
- MCA aneurysms: Better outcomes with clipping (higher crossover rate from coil to clip)
- Bottom line: Long-term outcomes are similar; treatment choice should be individualized by aneurysm anatomy and location
Board Pearls
- ISAT = coiling superior for ruptured aneurysms amenable to both treatments (anterior circulation, good grade) — 23.5% relative risk reduction in death/dependency at 1 year
- BRAT = similar long-term outcomes but confirmed MCA favors clipping and posterior circulation favors coiling
- Coiling has higher retreatment rates (~17% vs. ~4%); late target-aneurysm rebleeding is rare in both arms (absolute rates <1%) but slightly higher with coiling (Molyneux 2015)
Factors Favoring Clipping vs. Coiling
Decision-Making Framework
| Factor | Favors Clipping | Favors Coiling |
|---|---|---|
| Location | MCA bifurcation (easily accessible, broad-necked) | Posterior circulation (basilar tip, PICA); cavernous ICA |
| Neck morphology | Wide neck (dome:neck ratio <2) | Narrow neck (dome:neck ratio ≥2) |
| Branch vessels | Branches arising from aneurysm dome or neck | No critical branches incorporated |
| Age | Younger patients (longer durability needed) | Elderly patients (lower procedural morbidity) |
| Surgical risk | Good surgical candidate, low H&H grade | High surgical risk, poor clinical grade |
| Associated hematoma | Large intraparenchymal hematoma requiring evacuation | No mass-occupying hematoma |
| Retreatment concern | Lower retreatment rate (~4%) | Higher retreatment rate (~17%); requires imaging follow-up |
| Antiplatelet need | No antiplatelet requirement post-procedure | Stent-assisted coiling requires dual antiplatelet therapy |
Adjunctive Endovascular Techniques
Balloon-Assisted Coiling
- Temporary balloon inflation across aneurysm neck during coil placement to prevent coil herniation
- Useful for wide-necked aneurysms that cannot be coiled with simple technique
- No long-term antiplatelet requirement
Stent-Assisted Coiling
- Intracranial stent deployed across aneurysm neck as scaffold to retain coils
- Requires dual antiplatelet therapy (aspirin + clopidogrel) — challenging in acute SAH setting due to potential need for EVD or additional surgery
- Better for wide-necked aneurysms not amenable to simple or balloon-assisted coiling
Flow Diverters (Pipeline Embolization Device)
- Dense-mesh stent placed across aneurysm neck → redirects flow away from aneurysm sac → progressive thrombosis and endothelialization
- Indications: Large (≥10 mm) or giant (≥25 mm) aneurysms, wide-necked aneurysms, fusiform aneurysms, blister aneurysms
- Best for: ICA (paraclinoid/ophthalmic segment) aneurysms; increasingly used in other locations
- Requires dual antiplatelet therapy for 3–6 months, then aspirin long-term
- Complications: Delayed aneurysm rupture (~1–3%), perforator infarction, in-stent stenosis/thrombosis
- Aneurysm occlusion occurs over weeks to months (not immediate) — not ideal for acutely ruptured aneurysms unless no other option
Clinical Pearl
MCA aneurysms = clipping; basilar tip = coiling. This is the single most tested surgical decision point. MCA aneurysms have broad necks, incorporate branches, and are surgically accessible via Sylvian fissure. Basilar tip aneurysms are deep, surgically hazardous, and technically ideal for endovascular access. Flow diverters are reserved for large/giant or fusiform aneurysms where standard treatment fails.
Continue reading — sign in
The full note has more clinical pearls, tables, and board-focused tips. Free account, no fee.